Introduction
============

As the 8th most common cancer worldwide, renal cell carcinoma (RCC) accounts for 2--3% of all adult malignancies[@b1-cmar-10-1687] and causes approximately 140,000 deaths per year.[@b2-cmar-10-1687] Although most patients with RCC can be cured by surgical resection, more than 25% of patients still experience local recurrence or distant metastasis.[@b3-cmar-10-1687] Given that clear cell RCC (ccRCC) accounts for approximately 80% of all RCCs,[@b4-cmar-10-1687] it should be noted that a particular histologic subtype is accompanied by different manifestations and pharmacologic consequences.[@b5-cmar-10-1687] Therefore, ideally, the clinical significance of a particular prognostic factor should always be independently validated for each histologic subtype.

RCC with sarcomatoid differentiation is a rare variant of RCC that accounts for 1--8% of all RCC histologic subtypes.[@b6-cmar-10-1687] Histologically, sarcomatoid is a term used to describe morphologic changes within an RCC. Previous research demonstrates that sarcomatoid differentiation is associated with a more aggressive disease and poor outcome after surgical resection or immunotherapy.[@b7-cmar-10-1687],[@b8-cmar-10-1687] The International Society of Urological Pathology recommended that the presence of sarcomatoid differentiation should be classified as Grade 4 regardless of the histological subtype or nuclear grade.[@b9-cmar-10-1687] Given small sample sizes and different conditions, minimal evidence is available on the prognostic role of sarcomatoid differentiation for RCC.

To further clarify the prognostic and clinicopathological value of sarcomatoid differentiation in RCC, we conducted a systematic review and meta-analysis to evaluate whether the presence of sarcomatoid differentiation has a prognostic impact on cancer-specific survival (CSS), overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific mortality (CSM).

Materials and methods
=====================

Literature search
-----------------

In accordance with the preferred reporting items for systematic reviews and meta-analysis guideline,[@b10-cmar-10-1687] we systematically searched for relevant studies in PubMed, Embase, and Web of Science until January 2018. The following terms were included in the search strategy: "sarcomatoid differentiation," "renal cell cancer OR renal cell carcinoma", and "prognostic factor OR oncologic outcome." These terminologies were used in all possible combinations, and the language of publications was restricted to English. Moreover, the reference lists of the included articles were scanned manually for additional potentially relevant studies.

Inclusion and exclusion criteria
--------------------------------

Studies eligible for inclusion in our meta-analysis had to meet the following criteria: 1) studies that included RCC and where the expression of sarcomatoid differentiation was pathologically confirmed; 2) studies in which the association between sarcomatoid differentiation and the prognosis of RCC (CSS, OS, RFS, PFS, and CSM) were reported; and 3) studies wherein HRs and their 95% CIs for survival analysis were reported or could be computed from given data. The exclusion criteria were as follows: 1) reviews, case reports, conference records, and comments and non-original articles; 2) studies that did not analyze the sarcomatoid differentiation, clinicopathological features, and survival outcome; 3) studies with insufficient data to estimate the HRs and 95% CIs; and 4) studies that were not published in English. In addition, when multiple reports describing the same population were published, the most recent or most complete report was used.

Data extraction and quality assessments
---------------------------------------

According to the inclusion and exclusion criteria, 2 investigators independently extracted the following data from eligible studies: first author's name, year of publication, country, period of recruitment, study design, age of patients, gender ratio, number of patients, follow-up time, histology, nuclear grade, pathology tumor (pT) stage, and survival end point. If multivariate and univariate analyses were both conducted in the same study, only the results of multivariate analysis were extracted because this information is more accurate as it accounts for confounding factors. When disagreement occurred, the issue was resolved through discussion among the authors. The quality in prognosis studies[@b11-cmar-10-1687] tool was used to assess the methodological quality of each included study. Each study can be assessed by 6 important bias domains: study participation, study attrition, prognostic factor measurement, study confounding, outcome measurement, and statistical analysis and reporting. Studies from the analysis that are at high risk for any important bias were defined as low quality.

Statistical analysis
--------------------

The statistical processes in this meta-analysis were undertaken using Stata 12.0 (StataCorp, College Station, TX, USA). Dichotomous variables were calculated by HRs, and pooled HRs with 95% CIs were used to evaluate the association of sarcomatoid differentiation with RCC prognosis (CSS, OS, RFS, PFS, and CSM). Furthermore, we studied the associations between sarcomatoid differentiation and clinical parameters of RCC. Data about Fuhrman grade (III/IV vs I/II), pT stage (pT3--4 vs pT1--2), lymph node involvement (N1 vs N0), pathological types (ccRCC-only vs mixed type), and gender (male vs female) were continuous variables whereas average age was a dichotomous variable. Comparisons of continuous and dichotomous variables were pooled as standard mean differences (SMDs) and ORs.

Statistical heterogeneity among studies was assessed using Cochran's *Q* test and Higgins *I*[@b2-cmar-10-1687] statistic. When *I*[@b2-cmar-10-1687] \<50% or *p*~heterogeneity~ \>0.1, which indicates that no obvious heterogeneity existed among studies, the fixed effects (FE) model was applied; otherwise, the random-effects (RE) model was applied. To obtain a more precise evaluation of heterogeneity, subgroup analyses were conducted for CSS, OS, RFS, PFS, and CSM by geographical region, year of publication, pathological types, pT stage, Fuhrman grade, number of patients, and median follow-up. Publication bias was assessed using funnel plots and Egger's linear regression test. In addition, sensitivity analyses were used to estimate the robustness of the results by sequential omission of individual studies. A 2-tailed *p*-value \<0.05 was considered statistically significant.

Results
=======

Literature search
-----------------

The flowchart depicting the study selection procedure in this meta-analysis is shown in [Figure 1](#f1-cmar-10-1687){ref-type="fig"}. After the initial search of relevant databases, 5,848 potentially relevant citations were retrieved. In total, 4,906 studies were excluded by reviewing the title and abstract, including 2,783 duplicate reports, 1,770 irrelevant studies, and 353 non-research articles (non-human studies, letters, case reports, meeting records, and reviews). The full-texts of the 942 remaining articles were assessed, and 907 papers were excluded due to insufficient survival information or duplicated cohorts. Finally, in accordance with the inclusion criteria, 35 articles published from 2004 to 2017 about the association of sarcomatoid differentiation and RCC survival were eligible for the meta-analysis.

Study characteristics
---------------------

The characteristics of the 35 eligible studies[@b12-cmar-10-1687]--[@b46-cmar-10-1687] are presented in [Table 1](#t1-cmar-10-1687){ref-type="table"}. These studies enrolled 11,261 patients (59--1,437 per study), with a median follow-up ranging from 12.6 to 102 months. Most of the included studies had a retrospective design. Among the included studies, 10 were conducted in America, 7 in China, 6 in Korea, 5 in Europe, 4 at multiple centers, 1 in Mexico, 1 in Egypt, and 1 in Japan. CSS was evaluated in 17 studies, and OS was reported in 14 studies. Both PFS and RFS were reported in 7 studies, and CSM was reported in 5 studies. The characteristics, including tumor features and pathologic outcomes, are summarized in [Table 2](#t2-cmar-10-1687){ref-type="table"}. Sarcomatoid differentiation was detected in (792/11,261) 7.03% of pathological specimens of the included patients. Ten of the included studies were limited to ccRCC, whereas 25 studies involved various tumor types, including ccRCC, papillary RCC, chromophobe RCC, and unclassified variants. The quality in prognosis studies tool was applied to assess the methodological quality of the included studies, demonstrating that all studies were of high quality ([Table S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)).

Meta-analysis results
---------------------

Our meta-analysis demonstrated that sarcomatoid differentiation expression in RCC was associated with poor CSS (RE model, HR=1.46, 95% CI: 1.26--1.70; *p*\<0.001; *I***^2^**=75.2%; [Figure 2A](#f2-cmar-10-1687){ref-type="fig"}), OS (RE model, HR=1.59, 95% CI: 1.42--1.78, *p*\<0.001; *I***^2^**=46.5%; [Figure 2B](#f2-cmar-10-1687){ref-type="fig"}), PFS (RE model, HR=1.61, 95% CI: 1.35--1.91; *p*\<0.001; *I***^2^**=57.6%; [Figure 2C](#f2-cmar-10-1687){ref-type="fig"}), RFS (RE model, HR=1.60, 95% CI: 1.29--1.99, *p*\<0.001; *I***^2^**= 58.6%; [Figure 2D](#f2-cmar-10-1687){ref-type="fig"}), and CSM (RE model, HR=2.36, 95% CI: 1.64--3.41; *p*\<0.001; *I***^2^**=81.9%; [Figure 2E](#f2-cmar-10-1687){ref-type="fig"}). To explore the heterogeneity between these studies, the significance of sarcomatoid differentiation was evaluated further via subgroup analysis based on the main features, including geographical region, year of publication, pathological types, pT stage, Fuhrman grade, number of patients, and median follow-up ([Table 3](#t3-cmar-10-1687){ref-type="table"}). The results of subgroup analysis suggested sarcomatoid differentiation as a prognostic factor despite heterogeneity among some groups. Of note, heterogeneity decreased significantly in some models, such as geographical region in non-Asian (CSS, OS, and RFS), year of publication before 2013 (CSS, OS, RFS, and CSM), number of patients \<250 (CSS, OS, RFS, and CSM), (pT3--4) % ≥50 (CSS, OS, PFS, and CSM), median followup \<40 months (CSS, OS, RFS, and CSM), and mixed type pathology (OS and RFS).

To explore the significance of sarcomatoid differentiation in pathologic diagnosis, we evaluated the relationship between the expression of sarcomatoid differentiation and clinicopathological features. As shown in [Table 4](#t4-cmar-10-1687){ref-type="table"}, sarcomatoid differentiation was significantly related to TNM stage (III/IV vs I/II: OR=1.84, 95% CI: 1.12--3.03, *p*=0.017, [Figure S1A](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), Fuhrman grade (III/IV vs I/II: OR=8.37, 95% CI: 2.92--24.00, *p*\<0.001, [Figure S1B](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), lymph node involvement (N1 vs N0: OR=1.88, 95% CI: 1.08--3.28, *p*=0.026, [Figure S1C](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), and pathological type (ccRCC-only vs mixed type: OR=0.48, 95% CI: 0.29--0.80, *p*=0.005, [Figure S1D](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), However, no significant correlations were observed with regard to gender (male vs female, OR=0.86, 95% CI: 0.58--1.28, *p*=0.464, [Figure S1E](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)) and average age (SMD=−0.02, 95% CI: −0.20--0.17, *p*=0.868, [Figure S1F](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)). No significant heterogeneity was observed in those groups.

Sensitivity analysis
--------------------

In sensitivity analysis by sequential omission of individual studies, the pooled HR for CSS ranged from 1.37 (95% CI: 1.22--1.54) to 1.49 (95% CI: 1.28--1.74) ([Figure S2A](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)). Similarly, the pooled HR for OS ranged from 1.54 (95% CI: 1.37--1.72) to 1.62 (95% CI: 1.46--1.80) ([Figure S2B](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), for PFS from 1.53 (95% CI:1.31--1.79) to 1.68 (95% CI: 1.41--2.00) ([Figure S2C](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), for RFS from 1.47 (95% CI: 1.23--1.75) to 1.73 (95% CI: 1.39--2.16) ([Figure S2D](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)), and for CSM from 2.06 (95% CI: 1.48--2.87) to 2.72 (95% CI: 1.83--4.04) ([Figure S2E](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D166710.pdf)). These results indicated that the findings were reliable and robust.

Publication bias
----------------

Egger's tests and funnel plots were conducted to estimate publication bias in the present meta-analysis. As shown in [Figure 3](#f3-cmar-10-1687){ref-type="fig"}, the funnel plots indicated that the included studies (CSS, OS, RFS, and PFS) had no evident asymmetry. The *p*-values of the Egger's tests were all greater than 0.05 in CSS (*p*-Egger=0.723, [Figure 3A](#f3-cmar-10-1687){ref-type="fig"}), OS (*p*-Egger=0.925, [Figure 3B](#f3-cmar-10-1687){ref-type="fig"}), PFS (*p*-Egger=0.443, [Figure 3C](#f3-cmar-10-1687){ref-type="fig"}), and RFS (*p*-Egger=0.108, [Figure 3D](#f3-cmar-10-1687){ref-type="fig"}). However, a statistically significant publication bias was founded in CSM (*p*-Egger=0.003, [Figure 3E](#f3-cmar-10-1687){ref-type="fig"}).

Discussion
==========

The rate of incidence of RCC has rapidly increased by approximately 2% worldwide during the last decade.[@b47-cmar-10-1687] Although significant advancements have been made in managing renal masses, long-term survival remains unsatisfactory, and the vast majority of patients with RCC still die of their disease. Therefore, RCC patients should be closely followed up, and reliable prognostic biomarkers that evaluate postoperative risks and allow individualized treatment for RCC patients are necessary. In recent years, numerous studies have investigated a wide variety of prognostic factors, such as TNM stage,[@b13-cmar-10-1687] Fuhrman's grade, and tumor size.[@b48-cmar-10-1687] However, these prognostic variables cannot always make accurate predictions due to the limitation of significant tumor heterogeneity in RCC patients.[@b14-cmar-10-1687] Therefore, novel biomarkers that can distinguish high-risk RCC patients and improve clinical outcomes are desperately needed.

An RCC with sarcomatoid differentiation is a distinct subtype that is defined by the presence of atypical spindle cells and is similar to all forms of sarcoma.[@b49-cmar-10-1687] The reported incidence of sarcomatoid differentiation is between 0.7% and 13.2% of all RCCs,[@b50-cmar-10-1687] which is consistent with our result of 7.03% (792/11,261). Clinically, sarcomatoid differentiation in RCC is associated with more aggressive tumor biology, increased rates of recurrence, and poor survival.[@b28-cmar-10-1687] Furthermore, RCC with sarcomatoid differentiation demonstrates unfavorable responses to targeted therapy.[@b8-cmar-10-1687] According to the 2016 World Health Organization Classification, RCC with sarcomatoid differentiation should not recognized as a separate and distinct entity, indicating that the sarcomatoid component could occur in all types of RCC.[@b51-cmar-10-1687]

To date, several studies have examined the prognostic value of sarcomatoid differentiation for RCC patients. However, these results were not consistent. Gu et al[@b15-cmar-10-1687] demonstrated that the presence of sarcomatoid differentiation was significantly associated with poor oncologic outcomes (OS and PFS) for surgically treated RCC patients. Furthermore, Keegan et al[@b5-cmar-10-1687] confirmed that the sarcomatoid component was associated with poor survival even when encountered in low-stage disease. However, a study by Tosco et al[@b33-cmar-10-1687] found that sarcomatoid differentiation failed to independently predict CSM in surgically treated RCC patients. Similarly, Chen et al[@b48-cmar-10-1687] found that the sarcomatoid feature is not a prognostic factor of pT3 RCC for PFS and CSS. Zhang et al[@b49-cmar-10-1687] demonstrate that the presence of rhabdoid differentiation does not confer an increased risk of death from the largest study, to date, of patients with Grade 4 RCC. Although sarcomatoid differentiation is commonly recognized by clinicians as being associated with poor outcomes, no commonly accepted prognostic system for sarcomatoid RCC is currently available due to the low morbidity and lack of study data. With this objective in mind, we first sought to confirm that sarcomatoid differentiation is an independent prognostic feature for RCC patients.

Using the largest sample size to date, this meta-analysis is the most comprehensive study to systematically analyze the prognostic power of sarcomatoid differentiation in patients with RCC. We found that sarcomatoid differentiation was significantly associated with CSS (HR=1.46, *p*\<0.001), OS (HR=1.59, *p*\<0.001), PFS (HR=1.61, *p*\<0.001), RFS (HR=1.60, *p*\<0.001), and CSM (HR=2.36, *p*\<0.001) in RCC patients. In addition, subgroup analyses demonstrated that sarcomatoid differentiation remained a good biomarker regardless of the background of ethnic background, pT stage, nuclear grade, and tumor type. Given the lower sample size of the subgroup (PFS and median follow-up ≥40 months) with a different result (2 studies involving 1,720 patients), we can ignore the inconsistent result to some extent.

Our findings, furthermore, demonstrated that RCC cases exhibiting sarcomatoid differentiation are prone to experiencing a higher nuclear grade (OR=8.37, *p*\<0.001), increased pathological T stage (OR=1.84, *p*=0.017), lymph node involvement (OR=1.88, *p*=0.026), and mixed histologic types (OR=0.48, *p*=0.005). However, sarcomatoid differentiation is not associated with gender (OR=0.86, *p*=0.464) and average age (SMD= −0.02, *p*=0.868). Interestingly, although RCCs differ among histological subtypes, we observed no differences on comparing the positive expression of sarcomatoid differentiation between ccRCC and mixed type (CSS, OS, and RFS). In other words, sarcomatoid differentiation may be independently validated as a prognostic factor for each histologic subtype, and this information reflects the risk stratification in the clinical treatment of RCC.

However, several limitations of this study need to be acknowledged. First, significant heterogeneity was detected for several parameters. Although we selected random-effect or fixed-effect models based on heterogeneity, it still existed due to the differences in the included studies. Second, although a comprehensive search strategy was applied to determine eligible studies, it is possible that some eligible studies were not included, which may cause selection bias. Third, the criteria for the presence of sarcomatoid differentiation in pathologic specimens were inconsistent, which may potentially contribute to potential bias. Thus, rigorous morphological criteria should be conducted to standardize the diagnosis of sarcomatoid differentiation. Additionally, a publication bias existed in CSM, thus inflating the estimate for the association of sarcomatoid differentiation with CSM risk.

Conclusion
==========

Our results demonstrated that sarcomatoid differentiation expression was associated with poor pathological features and prognosis. These findings indicate that sarcomatoid differentiation is a potential adverse prognostic marker that could be utilized to divide risk stratification and formulate individualized treatments for patients with RCC. Considering the limitations of the present analysis, larger studies using standardized methods and criteria are required to verify the prognostic roles of sarcomatoid differentiation expression in RCC.
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###### 

Forest plots of studies evaluating the association between sarcomatoid differentiation and clinical outcome of patients with RCC: (**A**) CSS, (**B**) OS, (**C**) PFS, (**D**) RFS, and (**E**) CSM.

**Note:** Weights are from random-effects analysis.

**Abbreviations:** CSS, cancer-specific survival; OS, overall survival; RFS, recurrence-free survival; PFS, progression-free survival; CSM, cancer-specific mortality; RCC, renal cell carcinoma.
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###### 

Funnel plots of Egger evaluating possible publication bias for: (**A**) CSS, (**B**) OS, (**C**) PFS, (**D**) RFS, and (**E**) CSM.

**Abbreviations:** CSS, cancer-specific survival; OS, overall survival; RFS, recurrence-free survival; PFS, progression-free survival; CSM, cancer-specific mortality.
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###### 

Main characteristics of the eligible studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                           Year   Country        Recruitment period   No. of patients   Age (years)          Gender (m/f)   Follow-up (months)    Study design    Survival analysis
  ------------------------------------------------ ------ -------------- -------------------- ----------------- -------------------- -------------- --------------------- --------------- -------------------
  Zhang et al[@b12-cmar-10-1687]                   2017   China          2008--2009           602               Mean±SD\             422/180        Median (range)\       Retrospective   OS, RFS
                                                                                                                55±12.3                             67 (39--74)\                          

  Xie et al[@b13-cmar-10-1687]                     2017   China          2006--2015           209               Mean±SD\             96/113         Median (range)\       Retrospective   PFS
                                                                                                                47.7±12.0                           48.4 (10.7--129.9)\                   

  Wu et al[@b14-cmar-10-1687]                      2017   China          2004--2012           301               Median (range)\      206/95         Median (range)\       Retrospective   OS
                                                                                                                53 (4--831)\                        54.6 (3--121)\                        

  Gu et al[@b15-cmar-10-1687]                      2017   China          2006--2014           184               Mean±SD\             142/42         Mean±SD\              Retrospective   OS, PFS
                                                                                                                54.3±13.0                           23.3±14.6                             

  Gershman et al[@b16-cmar-10-1687]                2017   USA            1980--2010           138               Mean (range)\        91/47          Median (IQR)\         Retrospective   CSM
                                                                                                                63 (54--72)\                        102 (67.2--130.8)\                    

  Chipollini et al[@b17-cmar-10-1687]              2017   Multi-center   2000--2015           293               Median (IQR)\        NA             Median (IQR)\         Retrospective   CSS
                                                                                                                61 (54.7--70.3)\                    12.6 (4.47--30.3)\                    

  NguyenHoang et al[@b18-cmar-10-1687]             2016   China          2008--2009           392               Mean±SD\             116/276        Median (range)\       Retrospective   OS, RFS
                                                                                                                55.2±12.1                           73 (39--74)\                          

  Khor et al[@b19-cmar-10-1687]                    2016   USA            1985--2003           842               Median (range)\      527/315        Median (range)\       Retrospective   OS
                                                                                                                61.5 (22.4--89)\                    73.2 (0.12--273.6)\                   

  Lee et al[@b20-cmar-10-1687]                     2016   Korea          2006--2013           1,511             Median (range)\      1,077/434      Median (IQR)\         Retrospective   CSS
                                                                                                                57.6 (19--86)\                      36 (24--57)\                          

  Kara et al[@b21-cmar-10-1687]                    2016   USA            2005--2013           264               NA                   175/89         Median (IQR)\         Retrospective   CSS
                                                                                                                                                    16.8 (24--57)\                        

  Jeon et al[@b22-cmar-10-1687]                    2016   Korea          1994--2008           1,437             Mean±SD\             1,011/426      Mean (range)\         Retrospective   OS, CSS
                                                                                                                54.2±11.7                           68.6 (1.2--212.6)\                    

  Errarte et al[@b23-cmar-10-1687]                 2016   Spain          NA                   59                Mean (range)\        45/14          Mean (range)\         Retrospective   OS
                                                                                                                59 (25--83)\                        65 (1--240)\                          

  Yu et al[@b24-cmar-10-1687]                      2015   China          2007--2014           140               Mean (range)\        101/39         Median 32             Retrospective   OS, PFS
                                                                                                                57.3 (17--79)\                                                            

  Schiavina et al[@b25-cmar-10-1687]               2015   Italy          2000--2013           185               Mean±SD\             149/36         Median (IQR)\         prospective     CSM
                                                                                                                63.3±11.8                           32 (18--62)\                          

  Psutka et al[@b26-cmar-10-1687]                  2015   USA            1994--2008           283               Median (IQR)\        195/88         Median (IQR)\         Retrospective   CSM
                                                                                                                67 (60--72)\                        97.2 (69.6--116.4)\                   

  Lee et al[@b27-cmar-10-1687]                     2015   Korea          1994--2013           440               Median (range)\      286/154        Median (IQR)\         Retrospective   PFS, CSS
                                                                                                                56 (18--82)\                        69 (30--134)\                         

  Kim et al[@b28-cmar-10-1687]                     2015   USA            1999--2012           55                Mean±SD\             42/13          Mean (range)\         Retrospective   OS
                                                                                                                61.2±11.1                           21.5 (10.4--101)\                     

  Weiss et al[@b29-cmar-10-1687]                   2014   Germany        1994--2011           200               Median (range)\      129/71         Median 49             Retrospective   OS
                                                                                                                67 (37--86)\                                                              

  Teng et al[@b30-cmar-10-1687]                    2014   China          2004--2009           378               Mean±SD\             272/106        Median (range)\       Retrospective   CSS, RFS
                                                                                                                53.4±12.4                           60 (2--97)\                           

  Haddad et al[@b31-cmar-10-1687]                  2014   Multi-center   2000--2013           166               Median (range)\      108/58         Median (range)\       Retrospective   RFS, CSS, OS
                                                                                                                62 (24--84)\                        27.8 (1--148)\                        

  El-Mokadem                                       2014   UK             2001--2005           98                Mean±SD\             61/37          Median (IQR)\         Retrospective   RFS, CSS

  et al[@b32-cmar-10-1687]                                                                                      62.9±11.6                           95 (40.5--115.5)\                     

  Tosco et al[@b33-cmar-10-1687]                   2013   Multi-center   1988--2011           109               Median (range)\      71/38          Median (range)\       Retrospective   CSS
                                                                                                                62 (25--82)\                        52.7 (1.37--283)\                     

  Kruck et al[@b34-cmar-10-1687]                   2013   Germany        1993--2006           278               Mean±SD\             194/84         Median (IQR)\         Retrospective   CSS, OS
                                                                                                                62.2±12.5                           65 (20--100)\                         

  Kondo et al[@b35-cmar-10-1687]                   2013   Japan          1985--2011           68                Median (range)\      48/20          Median (range)\       Retrospective   CSS
                                                                                                                63 (19--79)\                        19 (0.1--144)\                        

  Volpe et al[@b36-cmar-10-1687]                   2012   Multi-center   1995--2007           291               Mean±SD\             NA             Median (IQR)\         Retrospective   CSM
                                                                                                                59.9±13.8                           44(24--73)\                           

  Sukov et al[@b37-cmar-10-1687]                   2012   USA            1970--2002           395               Median (range)\      327/68         Median (range)\       Retrospective   CSM
                                                                                                                65 (25--89)\                        33.6 (0--198)\                        

  Sameh et al[@b38-cmar-10-1687]                   2012   Egypt          2000--2010           112               Mean (range)\        77/35          Median (range)\       Retrospective   RFS
                                                                                                                59 (22--87)\                        24 (3--125)\                          

  Ku et al[@b39-cmar-10-1687]                      2011   Korea          1995--2005           82                Mean 57              67/15          Median (range)\       Retrospective   PFS, CSS
                                                                                                                                                    9 (0--73)\                            

  Rodríguez-Covarrubias et al[@b40-cmar-10-1687]   2010   Mexico         1980--2009           126               Mean±SD\             71/55          Median (range)\       Retrospective   PFS
                                                                                                                60.1±13.3                           20.5 (2--228)\                        

  Poon et al[@b41-cmar-10-1687]                    2009   USA            1988--2007           230               Median (IQR)\        149/81         Median (IQR)\         Retrospective   CSS
                                                                                                                64.5 (55.7--72.5)\                  24 (9--48)\                           

  Klatte et al[@b42-cmar-10-1687]                  2009   USA            2001--2007           343               Mean (range)\        240/103        Median (range)\       Retrospective   CSS
                                                                                                                60.7 (24--85)\                      21 (2--67)\                           

  Coons et al[@b43-cmar-10-1687]                   2009   USA            1988--2006           128               Median (range)\      95/33          Median (range)\       Retrospective   CSS, OS, RFS
                                                                                                                64 (35--87)\                        25.2 (0--124)                         

  Kwak et al[@b44-cmar-10-1687]                    2007   Korea          1990--2004           186               Median (range)\      151/35         Median (IQR)\         Retrospective   PFS, OS
                                                                                                                58 (20--79)\                        17.4 (24--78.9)\                      

  Lee et al[@b45-cmar-10-1687]                     2006   Korea          1993--2003           485               Median (range)\      360/125        Median (range)\       Retrospective   CSS
                                                                                                                55 (26--81)\                        26.9 (4--96.9)\                       

  Sanchez-Ortiz et al[@b46-cmar-10-1687]           2004   USA            1992--2002           251               NA                   165/86         NA                    Retrospective   CSS
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** m/f, male/female; NA, data not applicable; CSS, cancer-specific survival; OS, overall survival; RFS, recurrence-free survival; PFS, progression-free survival; CSM, cancer-specific mortality.

###### 

Tumor characteristics of the eligible studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            Staging system   Grading system   Sarcomatoid + /sarcomatoid −   Stages 1--2/3--4   Grades 1--2/3--4   ccRCC/no-ccRCC   Tumor size (cm)
  ------------------------------------------------ ---------------- ---------------- ------------------------------ ------------------ ------------------ ---------------- -----------------
  Zhang et al[@b12-cmar-10-1687]                   NA               Fuhrman          26/576                         450/152            337/265            602/0            Mean±SD\
                                                                                                                                                                           4.0±2.55

  Xie et al[@b13-cmar-10-1687]                     2010 AJCC        Fuhrman          13/196                         189/20             196/13             0/209            Mean±SD\
                                                                                                                                                                           5.3±3.6

  Wu et al[@b14-cmar-10-1687]                      2010 AJCC        WHO              13/288                         265/36             225/76             301/0            NA

  Gu et al[@b15-cmar-10-1687]                      2010 AJCC        Fuhrman          53/110                         0/163              83/55              135/8            Mean±SD\
                                                                                                                                                                           6.8±3.5

  Gershman et al[@b16-cmar-10-1687]                2010 AJCC        WHO/ISUP         30/108                         31/107             6/132              105/33           Median (IQR)\
                                                                                                                                                                           10 (8--13)\

  Chipollini et al[@b17-cmar-10-1687]              2016AJCC         Fuhrman          56/236                         0/293              30/263             261/32           NA

  NguyenHoang et al[@b18-cmar-10-1687]             2010 AJCC        Fuhrman          5/201                          292/100            259/133            392/0            Mean±SD\
                                                                                                                                                                           4.3±2.6

  Khor et al[@b19-cmar-10-1687]                    2010 AJCC        Fuhrman          20/822                         630/212            265/577            842/0            Median (range)\
                                                                                                                                                                           4.2 (0.6--20)\

  Lee et al[@b20-cmar-10-1687]                     2010 AJCC        Fuhrman          48/1,463                       1,305/206          825/686            1,260/251        Median (range)\
                                                                                                                                                                           4.33 (0.5--16)\

  Kara et al[@b21-cmar-10-1687]                    2010 AJCC        Fuhrman          159/109                        33/231             0/264              223/41           NA

  Jeon et al[@b22-cmar-10-1687]                    2010 AJCC        Fuhrman          28/1,409                       1,228/209          686/751            1,236/201        Mean±SD\
                                                                                                                                                                           5.1±3.3

  Errarte et al[@b23-cmar-10-1687]                 2010 AJCC        Fuhrman          4/55                           32/27              24/35              59/0             Median (range)\
                                                                                                                                                                           7.9 (2--19)\

  Yu et al[@b24-cmar-10-1687]                      2010 AJCC        Fuhrman          9/131                          0/140              NA                 125/15           NA

  Schiavina et al[@b25-cmar-10-1687]               2009 AJCC        Fuhrman          17/168                         0/185              46/139             150/35           Mean±SD\
                                                                                                                                                                           8.05±2.8

  Psutka et al[@b26-cmar-10-1687]                  2009 AJCC        Fuhrman          7/276                          214/69             151/132            233/50           Median (IQR)\
                                                                                                                                                                           5 (3--7.5)\

  Lee et al[@b27-cmar-10-1687]                     2009 AJCC        Fuhrman          17/433                         188/152            165/266            335/65           Median (range)\
                                                                                                                                                                           6.5 (1.2--32)\

  Kim et al[@b28-cmar-10-1687]                     2002 AJCC        WHO              20/35                          19/36              NA                 41/14            Mean±SD\
                                                                                                                                                                           9.9±4.4

  Weiss et al[@b29-cmar-10-1687]                   2009 AJCC        Fuhrman          5/195                          0/200              142/58             180/20           MA

  Teng et al[@b30-cmar-10-1687]                    2009 AJCC        Fuhrman          4/378                          346/32             200/178            378/0            Mean±SD\
                                                                                                                                                                           4.6±2.6

  Haddad et al[@b31-cmar-10-1687]                  2009 AJCC        Fuhrman          21/145                         0/166              13/153             149/17           Median (range)\
                                                                                                                                                                           10.5 (2.2--29)\

  El-Mokadem et al[@b32-cmar-10-1687]              2009 AJCC        Fuhrman          6/74                           50/30              31/49              80/0             NA

  Tosco et al[@b33-cmar-10-1687]                   2009 AJCC        Fuhrman          5/104                          49/60              40/69              88/21            Median (range)\
                                                                                                                                                                           7.5 (2--21)\

  Kruck et al[@b34-cmar-10-1687]                   2010 AJCC        Fuhrman          19/258                         169/109            234/44             278/0            Mean±SD\
                                                                                                                                                                           5.26±2.91

  Kondo et al[@b35-cmar-10-1687]                   2009 AJCC        Fuhrman          17/51                          0/68               33/35              0/68             Median (range)\
                                                                                                                                                                           10 (3.5--20)\

  Volpe et al[@b36-cmar-10-1687]                   2009 AJCC        Fuhrman          5/286                          245/46             175/116            0/291            Median (IQR)\
                                                                                                                                                                           4.6 (3.4--7)\

  Sukov et al[@b37-cmar-10-1687]                   2009 AJCC        Fuhrman          4/391                          357/38             247/148            109/16           Median (range)\
                                                                                                                                                                           8 (2.5--20)\

  Sameh et al[@b38-cmar-10-1687]                   2009 AJCC        Fuhrman          9/103                          0/112              45/51              96/16            Median (range)\
                                                                                                                                                                           8.1 (4--16)\

  Ku et al[@b39-cmar-10-1687]                      2002 AJCC        Fuhrman          24/58                          26/56              17/65              82/0             NA

  Rodríguez-Covarrubias et al[@b40-cmar-10-1687]   2002 AJCC        Fuhrman          11/115                         2/124              62/60              102/24           Mean±SD\
                                                                                                                                                                           9.03±5.2

  Poon et al[@b41-cmar-10-1687]                    2002 AJCC        Fuhrman          7/223                          0/230              138/92             153/77           NA

  Klatte et al[@b42-cmar-10-1687]                  2002 AJCC        Fuhrman          27/316                         198/145            181/162            343/0            Mean (range)\
                                                                                                                                                                           7.1 (0.8--25)\

  Coons et al[@b43-cmar-10-1687]                   2002 AJCC        Fuhrman          18/110                         0/128              40/103             105/23           Median (range)\
                                                                                                                                                                           9.9 (3.5--21)\

  Kwak et al[@b44-cmar-10-1687]                    2002 AJCC        Fuhrman          42/144                         86/100             55/131             152/34           NA

  Lee et al[@b45-cmar-10-1687]                     1997 AJCC        Fuhrman          10/466                         382/103            264/221            419/66           NA

  Sanchez-Ortiz et al[@b46-cmar-10-1687]           1997 AJCC        Fuhrman          33/218                         184/67             85/166             203/48           Mean 7.9
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** NA, data not applicable; AJCC, American Joint Committee on Cancer classification; WHO/ISUP, World Health Organization/International Society of Urological Pathology classification; ccRCC, clear cell renal cell carcinoma.

###### 

Summary and subgroup analysis for the eligible studies

  Analysis specification   No. of studies   Study heterogeneity   Effects model   Pooled HR (95% CI)   *p*-value           
  ------------------------ ---------------- --------------------- --------------- -------------------- ------------------- ---------
  **CSS**                                                                                                                  
  Overall                  17               75.2                  \<0.001         Random               1.46 (1.26,1.70)    \<0.001
  Geographical region                                                                                                      
   Asia                    7                86.9                  \<0.001         Random               1.72 (1.21,2.43)    0.002
   Non-Asian               10               0                     0.6             Fixed                1.33 (1.22,1.45)    \<0.001
  Year of publication                                                                                                      
   ≥2013                   8                86.6                  \<0.001         Random               1.60 (1.17,2.18)    0.003
   \<2013                  9                0                     0.47            Fixed                1.35 (1.23,1.48)    \<0.001
  No. of patients                                                                                                          
   ≥250                    10               85.1                  \<0.001         Random               1.55 (1.24,1.95)    \<0.001
   \<250                   7                0                     0.807           Fixed                1.36 (1.19,1.55)    \<0.001
  Stage (T~3~+T~4~, %)                                                                                                     
   ≥50                     7                0                     0.804           Fixed                1.35 (1.19,1.53)    \<0.001
   \<50                    10               85                    \<0.001         Random               1.56 (1.23,1.97)    0.001
  Grade (G~3~+G~4~, %)                                                                                                     
   ≥50                     11               73.5                  \<0.001         Random               1.42 (1.19,1.70)    \<0.001
   \<50                    6                79.1                  \<0.001         Random               1.58 (1.17,2.13)    0.003
  Median follow-up                                                                                                         
   ≥40 months              6                90.3                  \<0.001         Random               1.78 (1.14,2.78)    0.011
   \<40 months             10               0                     0.855           Fixed                1.31 (1.19,1.44)    \<0.001
  Pathological types                                                                                                       
   ccRCC-only              5                82                    \<0.001         Random               1.59 (1.13,2.23)    0.008
   mixed type              12               72.7                  \<0.001         Random               1.43 (1.20,1.70)    \<0.001
  **OS**                                                                                                                   
  Overall                  14               46.5                  0.029           Random               1.59 (1.42,1.78)    \<0.001
  Geographical region                                                                                                      
   Asia                    8                38.1                  0.126           Fixed                1.72 (1.52,1.94)    \<0.001
  Non-Asian                6                22.5                  0.264           Fixed                1.37 (1.17,1.62)    \<0.001
  Year of publication                                                                                                      
   ≥2013                   9                39.7                  0.103           Fixed                1.68 (1.53,1.84)    \<0.001
   \<2013                  5                43.1                  0.134           Fixed                1.42 (1.23,1.53)    \<0.001
  No. of patients                                                                                                          
   ≥250                    8                52.6                  0.039           Random               1.77 (1.49,2.09)    \<0.001
   \<250                   6                0                     0.516           Fixed                1.45 (1.30,1.62)    \<0.001
  Stage (T~3~+T~4~, %)                                                                                                     
   ≥50                     7                13.6                  0.326           Fixed                1.47 (1.31,1.66)    \<0.001
   \<50                    7                56.3                  0.033           Random               1.73 (1.45,2.07)    \<0.001
  Grade (G~3~+G~4~, %)                                                                                                     
   ≥50                     6                55.3                  0.048           Random               1.52 (1.27,1.81)    \<0.001
   \<50                    6                49.6                  0.078           Random               1.76 (1.47,2.12)    \<0.001
  Median follow-up                                                                                                         
   ≥40 months              8                52.6                  0.039           Random               1.77 (1.49,2.09)    \<0.001
   \< 40 months            6                0                     0.516           Fixed                1.45 (1.30,1.62)    \<0.001
  Pathological types                                                                                                       
   ccRCC-only              6                48.4                  0.085           Random               1.82 (1.51,2.19)    \<0.001
   mixed type              8                1                     0.422           Fixed                1.47 (1.33,1.62)    \<0.001
  **PFS**                                                                                                                  
  Overall                  7                57.6                  0.028           Random               1.61 (1.35,1.91)    \<0.001
  Year of publication                                                                                                      
   ≥2013                   4                67.2                  0.028           Random               1.60 (1.20,2.13)    0.001
   \<2013                  3                59.6                  0.094           Random               1.62 (1.26,52.08)   \<0.001
  No. of patients                                                                                                          
   ≥250                    2                0                     0.843           Fixed                1.38 (1.15,1.67)    0.001
   \<250                   5                64.6                  0.023           Random               1.73 (1.37,2.19)    \<0.001
  Median follow-up                                                                                                         
   ≥40 months              2                79.8                  0.026           Random               1.84 (0.95,3.53)    0.068
   \<40 months             5                55.5                  0.061           Random               1.57 (1.31,1.88)    \<0.001
  Stage (T~3~+T~4~, %)                                                                                                     
   ≥50                     5                55.5                  0.061           Random               1.57 (1.31,1.88)    \<0.001
   \<50                    2                79.8                  0.026           Random               1.84 (0.95,3.53)    0.068
  Grade (G~3~+G~4~, %)                                                                                                     
   ≥50                     4                45.8                  0.137           Random               1.55 (1.27,1.88)    \<0.001
   \<50                    2                54.1                  0.140           Random               2.02 (1.40,2.93)    \<0.001
  **RFS**                                                                                                                  
  Overall                  7                58.6                  0.025           Random               1.60 (1.29,1.99)    \<0.001
  Geographical region                                                                                                      
   Asia                    3                15.1                  0.308           Fixed                2.06 (1.58,2.70)    \<0.001
  non-Asian                4                0                     0.747           Fixed                1.29 (1.141.46)     \<0.001
  Year of publication                                                                                                      
   ≥2013                   5                24.2                  0.260           Fixed                1.81 (1.46,2.25)    \<0.001
   \<2013                  2                0                     0.720           Fixed                1.25 (1.09,1.44)    0.001
  No. of patients                                                                                                          
   ≥250                    3                15.1                  0.308           Fixed                2.06 (1.58,2.70)    \<0.001
   \<250                   4                0                     0.747           Fixed                1.29 (1.141.46)     \<0.001
  Stage (T~3~+T~4~, %)                                                                                                     
   ≥50                     3                0                     0.608           Fixed                1.29 (1.13,1.46)    \<0.001
   \<50                    4                2.4                   0.380           Fixed                1.97 (1.56,2.47)    \<0.001
  Grade (G~3~+G~4~, %)                                                                                                     
   ≥50                     4                0                     0.747           Fixed                1.29 (1.14,1.46)    \<0.001
   \<50                    3                15.1                  0.308           Fixed                2.06 (1.58,2.70)    \<0.001
  Median follow-up                                                                                                         
   ≥40 months              3                34.3                  0.218           Fixed                1.99 (1.40,2.82)    \<0.001
   \<40 months             4                34.9                  0.203           Fixed                1.39 (1.14,1.69)    0.001
  Pathological types                                                                                                       
   ccRCC-only              4                2.4                   0.380           Fixed                1.97 (1.56,2.47)    \<0.001
   mixed type              3                0                     0.608           Fixed                1.29 (1.13,1.46)    \<0.001
  **CSM**                                                                                                                  
  Overall                  5                81.9                  \<0.001         Random               2.36 (1.64,3.41)    \<0.001
  Year of publication                                                                                                      
   ≥2013                   3                73.3                  0.024           Random               1.86 (1.35,2.57)    \<0.001
   \<2013                  2                0                     0.432           Fixed                3.56 (2.49,5.11)    \<0.001
  No. of patients                                                                                                          
   ≥250                    3                0                     0.537           Fixed                3.24 (2.47,4.27)    \<0.001
   \<250                   2                0                     0.343           Fixed                1.57 (1.34,1.85)    \<0.001
  Median follow-up                                                                                                         
   ≥40 months              3                0                     0.537           Fixed                3.24 (2.47,4.27)    \<0.001
   \<40 months             2                0                     0.343           Fixed                1.57 (1.34,1.85)    \<0.001
  Stage (T~3~+T~4~, %)                                                                                                     
   ≥50                     2                0                     0.343           Fixed                1.57 (1.34,1.85)    \<0.001
   \<50                    3                0                     0.537           Fixed                3.24 (2.47,4.27)    \<0.001
  Grade (G~3~+G~4~, %)                                                                                                     
   ≥50                     2                0                     0.343           Fixed                1.57 (1.34,1.85)    \<0.001
   \<50                    3                0                     0.537           Fixed                3.24 (2.47,4.27)    \<0.001

**Abbreviations:** CSS, cancer-specific survival; OS, overall survival; RFS, recurrence-free survival; PFS, progression-free survival; CSM, cancer-specific mortality; ccRCC, clear cell renal cell carcinoma.

###### 

Meta-analysis of the association between sarcomatoid differentiation and clinicopathological features of RCC

  Variables                                       Studies   Pooled OR/SMD   95% CI        *p*-value   Model   Heterogeneity *I*[@b2-cmar-10-1687] (%)   *p*~heterogeneity~ value
  ----------------------------------------------- --------- --------------- ------------- ----------- ------- ----------------------------------------- --------------------------
  TNM stage (III/IV vs I/II)                      4         1.84            1.12--3.03    0.017       FE      0                                         0.896
  Fuhrman grade (III/IV vs I/II)                  3         8.37            2.92--24.00   \<0.001     FE      0                                         0.457
  Lymph node involvement (N1 vs N0)               2         1.88            1.08--3.28    0.026       FE      21.3                                      0.26
  Pathological types (ccRCC-only vs mixed type)   4         0.48            0.29--0.80    0.005       FE      29.8                                      0.234
  Gender (male vs female)                         5         0.86            0.58--1.28    0.464       FE      0                                         0.67
  Average age                                     4         −0.02           −0.20--0.17   0.868       FE      0                                         0.908

**Abbreviations:** RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; SMD, standard mean difference.

[^1]: These authors contributed equally to this work
